BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations

  Kymera Therapeutics, Inc. today announced the appointment of Vijay Sabesan as Senior Vice President, Technical Operations.

  December 6, 2021

   · 

  5 min read
• Biotech Beach

  Phylex Biosciences Announces Development Of SARS-CoV-2 Delta And Omicron Bivalent Vaccine For 2022

  The new omicron variant is a game changer as current vaccine producers have recognized that new SARS-CoV-2 vaccines will be necessary to combat this new threat.

  December 6, 2021

   · 

  3 min read
• Drug Development

  Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

  Acurx Pharmaceuticals, Inc. announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022.

  December 6, 2021

   · 

  8 min read
• Genetown

  Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and Zetta Venture Partners

  Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round.

  December 6, 2021

   · 

  3 min read
• Business

  AnHeart Therapeutics Appoints Hua Zheng, M.D, Ph.D, as SVP, Head of Global Regulatory Affairs

  AnHeart Therapeutics Appoints Hua Zheng , M.D, Ph.D, as SVP, Head of Global Regulatory Affairs.

  December 6, 2021

   · 

  3 min read
• Biotech Bay

  Agilent Announces the Cary 3500 UV-Vis Spectrophotometer Compatibility with OpenLab

  Agilent Technologies Inc. (NYSE: A) has announced that the Agilent Cary 3500 UV-Vis Spectrophotometer is now compatible with the Agilent OpenLab software suite of products.

  December 6, 2021

   · 

  3 min read
• Genetown

  PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States

  PharmaEssentia’s BESREMi ® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States.

  December 6, 2021

   · 

  14 min read
• Drug Development

  180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

  180 Life Sciences Corp. today provided follow-up information on the top line results of Oxford University and the Company’s Phase 2b clinical trial for Dupuytren’s disease announced on December 1, 2021.

  December 6, 2021

   · 

  8 min read
• Drug Development

  Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

  Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol ® Cyclo™ for the Treatment of Alzheimer’s Disease.

  December 6, 2021

   · 

  6 min read
• Biotech Beach

  Emmaus Life Sciences’ Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition

  Emmaus Life Sciences, Inc. (OTCQX: EMMA), today announced that data on Endari®, the company’s prescription L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition.

  December 6, 2021

   · 

  3 min read